TY - JOUR
T1 - Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study
AU - Salpekar, Jay A.
AU - Joshi, Paramjit T.
AU - Axelson, David A.
AU - Reinblatt, Shauna P.
AU - Yenokyan, Gayane
AU - Sanyal, Abanti
AU - Walkup, John T.
AU - Vitiello, Benedetto
AU - Luby, Joan L.
AU - Wagner, Karen Dineen
AU - Nusrat, Nasima
AU - Riddle, Mark A.
N1 - Publisher Copyright:
© 2015 American Academy of Child and Adolescent Psychiatry.
PY - 2015
Y1 - 2015
N2 - Objective To assess the efficacy of mood-stabilizing medications for depression and suicidality in pediatric bipolar disorder. Method The Treatment of Early Age Mania (TEAM) study is a multicenter, prospective, randomized, masked comparison of divalproex sodium (VAL), lithium carbonate (LI), and risperidone (RISP) in an 8-week parallel clinical trial. A total of 279 children and adolescents with DSM-IV diagnoses of bipolar I disorder, mixed or manic, aged 6 to 15 years were enrolled. The primary outcome measure was improvement on the Clinical Global Impression scale for depression (CGI-BP-I-D). Secondary outcome measures included the Children's Depression Rating Scale (CDRS-R) and suicidality status. Statistics included longitudinal analysis of outcomes using generalized linear mixed models with random intercept both for the complete data set and by using last observation carried forward. Results CGI-BP-I-D ratings were better in the RISP group (60.7%) as compared to the LI (42.2%; p =.03) or VAL (35.0%; p =.003) groups from baseline to the end of the study. CDRS scores in all treatment groups improved equally by study end. In week 1, scores were lower with RISP compared to VAL (mean = 4.72, 95% CI = 2.67, 6.78), and compared to LI (mean = 3.63, 95% CI = 1.51, 5.74), although group differences were not present by the end of the study. Suicidality was infrequent, and there was no overall effect of treatment on suicidality ratings. Conclusion Depressive symptoms, present in the acutely manic or mixed phase of pediatric bipolar disorder, improved with all 3 medications, though RISP appeared to yield more rapid improvement than LI or VAL and was superior using a global categorical outcome.
AB - Objective To assess the efficacy of mood-stabilizing medications for depression and suicidality in pediatric bipolar disorder. Method The Treatment of Early Age Mania (TEAM) study is a multicenter, prospective, randomized, masked comparison of divalproex sodium (VAL), lithium carbonate (LI), and risperidone (RISP) in an 8-week parallel clinical trial. A total of 279 children and adolescents with DSM-IV diagnoses of bipolar I disorder, mixed or manic, aged 6 to 15 years were enrolled. The primary outcome measure was improvement on the Clinical Global Impression scale for depression (CGI-BP-I-D). Secondary outcome measures included the Children's Depression Rating Scale (CDRS-R) and suicidality status. Statistics included longitudinal analysis of outcomes using generalized linear mixed models with random intercept both for the complete data set and by using last observation carried forward. Results CGI-BP-I-D ratings were better in the RISP group (60.7%) as compared to the LI (42.2%; p =.03) or VAL (35.0%; p =.003) groups from baseline to the end of the study. CDRS scores in all treatment groups improved equally by study end. In week 1, scores were lower with RISP compared to VAL (mean = 4.72, 95% CI = 2.67, 6.78), and compared to LI (mean = 3.63, 95% CI = 1.51, 5.74), although group differences were not present by the end of the study. Suicidality was infrequent, and there was no overall effect of treatment on suicidality ratings. Conclusion Depressive symptoms, present in the acutely manic or mixed phase of pediatric bipolar disorder, improved with all 3 medications, though RISP appeared to yield more rapid improvement than LI or VAL and was superior using a global categorical outcome.
KW - bipolar
KW - clinical trial
KW - depression
KW - pediatrics
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=84951304924&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951304924&partnerID=8YFLogxK
U2 - 10.1016/j.jaac.2015.09.016
DO - 10.1016/j.jaac.2015.09.016
M3 - Article
C2 - 26598475
AN - SCOPUS:84951304924
SN - 0890-8567
VL - 54
SP - 999-1007.e4
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
IS - 12
ER -